Axsome Therapeutics Inc (AXSM) - Total Assets
Based on the latest financial reports, Axsome Therapeutics Inc (AXSM) holds total assets worth $713.61 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Axsome Therapeutics Inc's book value for net asset value and shareholders' equity analysis.
Axsome Therapeutics Inc - Total Assets Trend (2013–2025)
This chart illustrates how Axsome Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Axsome Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Axsome Therapeutics Inc's total assets of $713.61 Million consist of 85.4% current assets and 14.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.8% |
| Accounts Receivable | $224.46 Million | 32.5% |
| Inventory | $27.94 Million | 4.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $40.52 Million | 5.9% |
| Goodwill | $12.04 Million | 1.8% |
Asset Composition Trend (2013–2025)
This chart illustrates how Axsome Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Axsome Therapeutics Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Axsome Therapeutics Inc's current assets represent 85.4% of total assets in 2025, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 46.8% of total assets in 2025, down from 99.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 32.5% of total assets.
Axsome Therapeutics Inc Competitors by Total Assets
Key competitors of Axsome Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Axsome Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 2.03 | 6.20 |
| Quick Ratio | 1.32 | 1.96 | 6.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $172.00 Million | $250.72 Million | $118.79 Million |
Axsome Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Axsome Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 204.81 |
| Latest Market Cap to Assets Ratio | 16.22 |
| Asset Growth Rate (YoY) | 21.3% |
| Total Assets | $689.80 Million |
| Market Capitalization | $11.19 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Axsome Therapeutics Inc's assets at a significant premium (16.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Axsome Therapeutics Inc's assets grew by 21.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Axsome Therapeutics Inc (2013–2025)
The table below shows the annual total assets of Axsome Therapeutics Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $689.80 Million | +21.34% |
| 2024-12-31 | $568.50 Million | -3.36% |
| 2023-12-31 | $588.24 Million | +77.46% |
| 2022-12-31 | $331.48 Million | +277.60% |
| 2021-12-31 | $87.79 Million | -52.84% |
| 2020-12-31 | $186.13 Million | -15.60% |
| 2019-12-31 | $220.55 Million | +1334.07% |
| 2018-12-31 | $15.38 Million | -56.75% |
| 2017-12-31 | $35.56 Million | -6.95% |
| 2016-12-31 | $38.21 Million | -22.14% |
| 2015-12-31 | $49.08 Million | +1661.29% |
| 2014-12-31 | $2.79 Million | +32.85% |
| 2013-12-31 | $2.10 Million | -- |
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more